Humanized ANTI-SCG3 antibody
Humanized ANTI-SCG3 antibody has been studied in 1 paper since 2025: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Jun 15, 2025: “Age-independent anti-angiogenic therapy for choroidal neovascularization by targeting secretogranin III”.
1 paper studies it1 findingUpdated
See all 1 papers on humanized ANTI-SCG3 antibody
At a glance
The findings reach mice, none yet in people. 1 lab in 1 country.
Mice: a single group. Cells, worms or flies and humans: nothing yet.
- 1 lab in 1 country
- Funders: National Eye Institute and 2 more
- 1 of 1 finding with company ties
- Animals1
What did studies of humanized ANTI-SCG3 antibody find?
1Studies of humanized ANTI-SCG3 antibody measured one outcome, choroidal neovascularization.
Choroidal neovascularization
downin mice1
1 study
Choroidal neovascularization
downin mice1
Humanized ANTI-SCG3 antibody decreases choroidal neovascularization in mice (laser-induced CNV).
Animalslaser-induced CNVhumanized